The first dosing of TEW-7197 in a cancer patient in the USA
Aug 05, 2014MILESTONESHit 514
MedPacto, Inc. has finished the first dosing of TEW-7197 in human on 4th of August, 2014 in Nashville, USA. (NCT02160106) TEW-7197 is the forefront asset of Medpacto's oncology pipeline and it is for cancer patients of solid tumors. The phase I trial is planned to be completed in April of 2016 and its interim analysis after a phase of dose escalation is expected to be conducted in the middle of 2015.
|Previous||Clinical trial of TEW-7197 starts its first step.|
|Next||MedPacto Announces Clinical Collaboration with MSD to Evaluate Vactosertib, an Investigational TGF-β Type I Receptor Inhibitor, in combination with KEYTRUDA® (pembrolizumab)|